Psoriasis is a common systemic disease that affecting 2 - 4 percent of the population. The care of patients with moderate to severe psoriasis often requires systemic treatment with potent drugs.
Psoriasis causes an impact on quality of life comparable to asthma and insulin-treated diabetes. Psoriasis is a disease with inflammation of the skin, and in a third of the patients also the joints. Psoriasis is associated with an increased risk of metalbolic syndrome cardiovascular disease and depression.
PsoReg’s purpose is:
The aim of the registry is to include all psoriasis patients in the country who receive systemic therapy. In our most urgent target group – patients receiving biological therapy from dermatology clinics, 65 % of the patients are registered.
The latest annual report can be found on PsoReg's website.
Note: Variable lists are updated on a regular basis and should therefore be seen as preliminary. For the latest version, please contact the registry.
Category: Other areas
Certification level: 2
Tack för att du hjälper oss!